ICU Medical (NASDAQ:ICUI) Issues FY 2024 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.400-5.700 for the period, compared to the consensus estimate of 5.220. The company issued revenue guidance of -. ICU Medical also updated its FY24 guidance to $5.40-5.70 EPS.

ICU Medical Stock Performance

NASDAQ ICUI opened at $171.96 on Friday. The company has a fifty day moving average of $176.32 and a two-hundred day moving average of $142.19. ICU Medical has a 1 year low of $82.82 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.08 and a current ratio of 2.29.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.35. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The business had revenue of $580.07 million during the quarter, compared to the consensus estimate of $574.77 million. On average, equities analysts anticipate that ICU Medical will post 3.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ICUI has been the subject of a number of recent research reports. KeyCorp increased their price objective on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday. Raymond James upped their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. StockNews.com cut ICU Medical from a “buy” rating to a “hold” rating in a research report on Tuesday. Jefferies Financial Group assumed coverage on ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective for the company. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Wednesday. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Insider Buying and Selling at ICU Medical

In other news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 16.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total value of $2,141,520.00. Following the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $18,665,666.78. The trade was a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,502 shares of company stock worth $6,573,496 in the last quarter. 6.70% of the stock is owned by insiders.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.